Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2026 07:00 ET | Source: The Hain Celestial Group, Inc.

Hain Celestial Reports Fiscal Third Quarter 2026 Financial Results

HOBOKEN, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through...
May 08, 2026 22:59 ET | Source: Momcozy

Momcozy Launches NightPro Baby Bottle Warmer, Designed to Make Nighttime Feeding Simpler, Faster, and More Precise

Momcozy Launches NightPro Baby Bottle Warmer, Designed to Make Nighttime Feeding Simpler, Faster, and More Precise
May 06, 2026 16:05 ET | Source: The Honest Company, Inc.

The Honest Company Reports First Quarter 2026 Results

Delivers Accelerated Revenue Growth, Led by Wipes & Personal Care Achieves Record Gross Margins, Fueled by Powering Honest GrowthReaffirms Full Year 2026 Financial Outlook LOS ANGELES, May 06,...
May 06, 2026 10:00 ET | Source: Bel U.S.

Bel Group Acquires Ingenuity Foods’ Brainiac® Brands to Expand Its Better-For-You Snacking Portfolio

Chicago and New York, May 06, 2026 (GLOBE NEWSWIRE) -- Bel Group, a global player in dairy, fruit, and veggie snacking and the maker of iconic brands Babybel®, GoGo squeeZ®, Boursin®, and The...
May 06, 2026 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO...
May 05, 2026 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene,...
May 03, 2026 18:00 ET | Source: Ex-CIA Jim Rickards

$9 Trillion Is Pouring Into American Manufacturing — And It’s Just Getting Started

Washington, D.C., May 03, 2026 (GLOBE NEWSWIRE) -- In less than a year, some of the largest corporations on Earth have committed a staggering $9 trillion to build, expand, and relocate manufacturing...
May 01, 2026 07:15 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will...
April 30, 2026 14:06 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease The safety and tolerability profile...
April 30, 2026 08:35 ET | Source: MBody AI Corp

Check-Cap ($MBAI) Advances NASDAQ Listing for MBody AI Merger

Company receives and responds to Nasdaq listing review comments; merger close on-track for first half of 2026 ISFIYA, Israel and LAS VEGAS, April 30, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd....